Ionis Pharmaceuticals Faces Investor Probe Following Failed Phase-3 Trial
Ionis Pharmaceuticals shares plummeted more than 20% on July 9, 2026, after the company revealed its CARDIO-TTRansform trial missed its primary endpoint. Law firm Levi & Korsinsky has launched an investigation into whether previous executive statements regarding the program’s progress misled investors about the study's risks and ultimate outcome.
















